We hypothesized that a subset of patients with tumor-negative, nonacute unilateral asymmetric sensorineural hearing loss (ASNHL) would show occult perilymphatic enhancement suggestive of blood-labyrinthine barrier (BLB) dysfunction on 10-min postcontrast three-dimensional (3D) heavily T2-weighted fluid-attenuated inversion recovery (hvT2-FLAIR) magnetic resonance imaging (MRI)....
✦ The floor
Discussion
Signed responses from readers of the wire.
No immediate change to routine audiology practice is warranted; this study adds to the diagnostic imaging evidence base and is more relevant to neuroradiology and ENT than to frontline hearing care.
Demonstrating blood-labyrinthine barrier dysfunction via accessible MRI protocols may offer a non-invasive diagnostic tool for otherwise unexplained asymmetric hearing loss, reducing the diagnostic uncertainty that burdens both clinicians and patients.
- 01Used 10-minute postcontrast 3D heavily T2-weighted FLAIR MRI to detect inner ear barrier dysfunction.
- 02Focused on tumor-negative patients with unilateral asymmetric sensorineural hearing loss.
- 03Perilymphatic enhancement was the imaging biomarker studied.
- 04Blood-labyrinthine barrier (the protective layer between blood vessels and inner ear fluid) dysfunction may explain some cases of asymmetric hearing loss.
- 05Published in a peer-reviewed ENT/otolaryngology journal.
Perilymphatic enhancement on 10-minute postcontrast 3D T2-FLAIR MRI is a marker of blood-labyrinthine barrier dysfunction in tumor-negative asymmetric SNHL.
studypartially supported- PMID
- 43026355
- DOI
- 10.1007/s00405-026-10806-8.
- Journal
- European Archives of Oto-Rhino-Laryngology
- Publication type
- research_article
- Evidence level
- 4
- Population
- Tumor-negative patients with unilateral asymmetric sensorineural hearing loss
- Intervention
- 10-minute postcontrast 3D heavily T2-weighted FLAIR MRI
Primary outcomes
Presence of perilymphatic enhancement as a marker of blood-labyrinthine barrier dysfunction